Beta Bionics Financial Ratios
NASDAQ: BBNXHealth CareMedical/Dental InstrumentsUSD
17.63+0.20 (+1.15%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Beta Bionics ratio analysis
Beta Bionics earned a net margin of -73.0% in FY 2025, up from -84.1% a year earlier. Gross margin was 55.4% compared with a median of 53.8% over the prior 2 years. Return on equity reached -25.5%, meaning Beta Bionics generated -0.25 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Beta Bionics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Price / sales | 11.83 | — | — |
| Price / book | 4.12 | — | — |
| Gross margin | 55.4% | 55.1% | 52.6% |
| Operating margin | -71.5% | -69.5% | -298.9% |
| Net margin | -73.0% | -84.1% | -367.6% |
| Free cash flow margin | -56.1% | -79.3% | -273.8% |
| Return on equity (ROE) | -25.5% | — | — |
| Return on assets (ROA) | -22.3% | -36.6% | -40.1% |
| Current ratio | 8.66 | 6.29 | 9.77 |
| Revenue growth | 53.9% | 442.9% | — |